病理学におけるAI市場 – 2030年までの世界予測

Al in Pathology Market - Global Forecast to 2030

病理学におけるAI市場 - ニューラルネットワーク(GAN、CNN、RNN)、機能(診断、画像解析、CDSS、データ管理、分析)、ユースケース(創薬、臨床ワークフロー)、エンドユーザー(病院、研究所、製薬/バイオテクノロジー)、および地域別 - 2030年までの世界予測
Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical Workflow), End User (Hospitals, Labs, Pharma/Biotech), & Region - Global Forecast to 2030

商品番号 : SMB-39671

出版社MarketsandMarkets
出版年月2025年5月
ページ数320
図表数323
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書
  • 製品開発/イノベーション: 病理学における AI 市場における今後の技術、研究開発活動、新製品および新サービスの発売に関する詳細な洞察。
  • 市場開発:提供内容、ニューラルネットワーク、機能、ユースケース、エンドユーザー、地域別に、収益性の高い新興市場に関する包括的な情報を提供します。
  • 市場多様化:製品ポートフォリオ、成長地域、最近の動向、市場への投資に関する包括的な情報を提供します。
  • 競合評価:主要企業の市場シェア、成長戦略、製品提供、および能力に関する詳細な評価を提供します。

The global AI in pathology market is expected to reach USD 347.39 million by 2030 from USD 107.43 million in 2025 at a high CAGR of 26.5% during the forecast period. According to the Personalized Medicine Coalition Report 2022, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases. Among the newly approved treatments are seven cancer drugs and three targeting other diseases and conditions. About 47% of these approved personalized therapies were indicated for treating cancer.

病理学におけるAI活用の世界市場は、予測期間中に26.5%の高いCAGR(年平均成長率)を維持し、2025年の1億743万米ドルから2030年には3億4,739万米ドルに達すると予想されています。パーソナライズ医療連合レポート2022によると、2023年にはFDA(米国食品医薬品局)が希少疾患患者向けの新たなパーソナライズ治療を16件承認しました。新たに承認された治療の中には、抗がん剤が7件、その他の疾患や病状を標的とした治療が3件含まれています。承認されたパーソナライズ治療の約47%は、がん治療を適応としていました

病理学におけるAI市場 - 2030年までの世界予測
ai-in-pathology-market-Overview

By use case, the drug discovery segment accounted for the largest share in 2024.

In 2024, the drug discovery segment accounted for the largest share of the AI in pathology market. Booming pharmaceutical & biotechnology R&D expenditure, the growing high-throughput screening & imaging, the increasing use of AI algorithms in pathology image analysis for the identification & classification of diseases, and the capability of AI to speed up the development of new therapeutics are expected to boost the market.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the AI in pathology market, by end user.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest market share due to advancements in drug discovery & development and the increasing use of AI in pathology for drug toxicology testing. Biotechnology companies use AI-based digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

病理学におけるAI市場 - 2030年までの世界予測 region
ai-in-pathology-market-Region

North America held the largest market share in 2024.

In 2024, North America accounted for the largest market share in the AI in pathology market due to strong investment in research & development and advanced healthcare infrastructure, which enables the use of high-tech machinery. The large patient pool and data availability help create a large database, which can be used to train the AI for higher accuracy and efficiency.

The breakdown of primary participants is as mentioned below:

  • By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Key Players

The key players in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel).

病理学におけるAI市場 - 2030年までの世界予測 ecosystem
ai-in-pathology-market-Ecosystem

Research Coverage

The report estimates the market size and future growth potential of various market segments based on offering, neural network, use case, end user, function, and region. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

Analysis of key drivers (development of CNNs and advanced AI models, Integration of AI into multiplex imaging, increasing cases of misdiagnoses in patients, benefits of AI-augmented telepathology, advancements in deep learning & image processing) restraints (high cost of digital pathology systems, limited AI expertise and varied regulatory guidelines for medical software, interoperability issues with legacy systems), opportunities (increasing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease progression) challenges (insufficient data for AI algorithms, data privacy, and ethical concerns, challenges associated with interpretability of AI models) influencing the growth of the AI in pathology market

  • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market
  • Market Development: Comprehensive information on the lucrative emerging markets by offering, neural network, function, use case, end user, and region
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players

Table of Contents

1               INTRODUCTION              28

1.1           STUDY OBJECTIVES       28

1.2           MARKET DEFINITION   28

1.3           STUDY SCOPE   29

1.3.1        MARKET SEGMENTATION AND GEOGRAPHIC SPREAD                 29

1.3.2        INCLUSIONS & EXCLUSIONS       30

1.4           YEARS CONSIDERED      31

1.5           CURRENCY CONSIDERED            31

1.6           KEY STAKEHOLDERS     32

2               RESEARCH METHODOLOGY       33

2.1           RESEARCH DATA              33

2.1.1        SECONDARY DATA          34

2.1.1.1    Key data from secondary sources       35

2.1.2        PRIMARY DATA 35

2.1.2.1    Revenue share analysis illustration    37

2.2           MARKET SIZE ESTIMATION         38

2.3           MARKET BREAKDOWN AND DATA TRIANGULATION                 44

2.4           RESEARCH ASSUMPTIONS           45

2.5           RESEARCH LIMITATIONS             45

2.5.1        METHODOLOGY-RELATED LIMITATIONS           45

2.5.2        SCOPE-RELATED LIMITATIONS                 45

2.6           RISK ASSESSMENT           46

3               EXECUTIVE SUMMARY  47

4               PREMIUM INSIGHTS       51

4.1           KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET  51

4.2           AI IN PATHOLOGY MARKET: REGIONAL MIX      52

4.3           ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION          53

4.4           GEOGRAPHIC GROWTH OPPORTUNITIES            54

5               MARKET OVERVIEW       55

5.1           INTRODUCTION              55

5.2           MARKET DYNAMICS       55

5.2.1        DRIVERS               56

5.2.1.1    Development of CNNs and advanced AI models            56

5.2.1.2    Integration of AI into multiplex imaging          56

5.2.1.3    Increasing cases of misdiagnoses in patients    57

5.2.1.4    Benefits of AI-augmented telepathology           57

5.2.1.5    Advancements in deep learning & image processing      58

5.2.2        RESTRAINTS      58

5.2.2.1    High cost of digital pathology systems              58

5.2.2.2    Limited AI expertise and varied regulatory guidelines for medical software 59

5.2.2.3    Inadequate interoperability issues with legacy systems  59

5.2.3        OPPORTUNITIES              60

5.2.3.1    Increasing demand for personalized medicines               60

5.2.3.2    Integration of multi-omics data          60

5.2.3.3    Predictive analytics for disease progression     61

5.2.4        CHALLENGES    61

5.2.4.1    Insufficient data for AI algorithms    61

5.2.4.2    Data privacy and ethical concerns     61

5.2.4.3    Challenges associated with interpretability of AI models                 62

5.3           TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS            63

5.4           INDUSTRY TRENDS         63

5.4.1        EVOLUTION OF AI IN PATHOLOGY         63

5.5           ECOSYSTEM ANALYSIS  64

5.6           VALUE CHAIN ANALYSIS               67

5.7           TECHNOLOGY ANALYSIS             68

5.7.1        KEY TECHNOLOGIES     68

5.7.1.1    Machine learning (ML) and artificial intelligence (AI) 68

5.7.1.2    Computer vision   68

5.7.2        COMPLEMENTARY TECHNOLOGIES       69

5.7.2.1    Cloud computing  69

5.7.3        ADJACENT TECHNOLOGIES       69

5.7.3.1    Telepathology       69

5.8           REGULATORY LANDSCAPE         70

5.8.1        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             70

5.8.2        REGULATIONS, BY REGION         70

5.8.2.1    North America      70

5.8.2.1.1 US           70

5.8.2.1.2 Canada   71

5.8.2.2    Europe   72

5.8.2.3    Asia Pacific            73

5.8.2.3.1 Japan      73

5.8.2.3.2 China      74

5.9           PRICING ANALYSIS          75

5.9.1        AVERAGE SELLING PRICE TREND, BY REGION   75

5.9.2        INDICATIVE PRICING ANALYSIS, BY OFFERING 75

5.10         PORTER’S FIVE FORCES ANALYSIS           76

5.10.1      THREAT FROM NEW ENTRANTS                77

5.10.2      THREAT FROM SUBSTITUTES   77

5.10.3      BARGAINING POWER OF SUPPLIERS       77

5.10.4      BARGAINING POWER OF BUYERS             77

5.10.5      INTENSITY OF COMPETITIVE RIVALRY 78

5.11         PATENT ANALYSIS          78

5.11.1      PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS        78

5.11.2      JURISDICTION AND TOP APPLICANT ANALYSIS                 79

5.12         KEY STAKEHOLDERS AND BUYING CRITERIA     82

5.12.1      KEY STAKEHOLDERS IN BUYING PROCESS           82

5.12.2      BUYING CRITERIA           83

5.13         END USER ANALYSIS      83

5.13.1      UNMET NEEDS OF END USERS  83

5.13.2      END USER EXPECTATIONS          84

5.14         KEY CONFERENCES AND EVENTS, 2025–2026        85

5.15         CASE STUDY ANALYSIS 86

5.15.1      CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES            86

5.15.2      CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS         86

5.15.3      CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES                 87

5.16         INVESTMENT & FUNDING SCENARIO     87

5.17         BUSINESS MODELS         88

5.18         IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET                 88

5.18.1      KEY USE CASES 89

5.18.2      AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY                 90

5.18.2.1  Accelerated biomarker discovery and clinical trial optimization                 90

5.18.3      IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS              91

5.18.3.1  Drug discovery & development market             91

5.18.3.2  Medical imaging & diagnostics market              91

5.18.4      USER READINESS AND IMPACT ASSESSMENT     92

5.18.4.1  User readiness       92

5.18.4.1.1                Pharmaceutical companies 92

5.18.4.1.2                Biopharmaceutical companies            92

5.18.4.2  Impact assessment                92

5.18.4.2.1                User A: Pharmaceutical companies   92

5.18.4.2.1.1            Implementation    92

5.18.4.2.1.2            Impact    93

5.18.4.2.2                User B: Biopharmaceutical companies              93

5.18.4.2.2.1            Implementation    93

5.18.4.2.2.2            Impact    93

5.19         TRADE ANALYSIS             93

5.19.1      IMPORT SCENARIO         94

5.19.2      EXPORT SCENARIO         95

5.20         US 2025 TARIFF 96

5.20.1      INTRODUCTION              96

5.20.2      KEY TARIFF RATES          97

5.20.3      PRICE IMPACT ANALYSIS             98

5.20.4      IMPACT ON COUNTRY/REGION                98

5.20.4.1  US           98

5.20.4.2  Europe   99

5.20.4.3  Asia Pacific            100

5.20.5      IMPACT ON END USE INDUSTRIES          100

6               AI IN PATHOLOGY MARKET, BY OFFERING         101

6.1           INTRODUCTION              102

6.2           END-TO-END SOLUTIONS           102

6.2.1        INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET   102

6.3           NICHE POINT SOLUTIONS           103

6.3.1        GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET  103

6.4           TECHNOLOGY  104

6.4.1        RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET  104

6.5           HARDWARE        105

6.5.1        HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET             105

6.6           MICROSCOPES  107

6.6.1        NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH          107

6.7           SCANNERS          108

6.7.1        IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND        108

6.8           STORAGE SYSTEMS         110

6.8.1        NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH                 110

7               AI IN PATHOLOGY MARKET, BY NEURAL NETWORK                 112

7.1           INTRODUCTION              113

7.2           CONVOLUTIONAL NEURAL NETWORKS (CNNS)                 113

7.2.1        FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET               113

7.3           GENERATIVE ADVERSARIAL NETWORKS (GANS)                 115

7.3.1        NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET            115

7.4           RECURRENT NEURAL NETWORKS (RNNS)            116

7.4.1        NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET         116

7.5           OTHER NEURAL NETWORKS      118

8               AI IN PATHOLOGY MARKET, BY FUNCTION        119

8.1           INTRODUCTION              120

8.2           IMAGE ANALYSIS              121

8.2.1        DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE       121

8.3           DIAGNOSTICS   122

8.3.1        RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET 122

8.4           WORKFLOW MANAGEMENT       123

8.4.1        OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE         123

8.5           DATA MANAGEMENT    124

8.5.1        EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND 124

8.6           PREDICTIVE ANALYTICS               125

8.6.1        GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET         125

8.7           CDSS     126

8.7.1        PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET                 126

8.8           AUTOMATED REPORT GENERATION     127

8.8.1        INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET 127

8.9           QUALITY ASSURANCE TOOLS    128

8.9.1        RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH                 128

9               AI IN PATHOLOGY MARKET, BY USE CASE            129

9.1           INTRODUCTION              130

9.2           DRUG DISCOVERY           130

9.2.1        TARGET IDENTIFICATION & SELECTION              133

9.2.1.1    Analysis of molecular and histological data for biomarker discovery to fuel market      133

9.2.2        TARGET VALIDATION   134

9.2.2.1    Increasing demand for precision medicines to drive market                 134

9.2.3        HIT IDENTIFICATION & PRIORITIZATION            135

9.2.3.1    Growing requirement for rapid analysis and cost efficiency to fuel uptake    135

9.2.4        HIT-TO-LEAD IDENTIFICATION               136

9.2.4.1    Advancements in ML to support market growth             136

9.2.5        LEAD OPTIMIZATION   137

9.2.5.1    Growing focus on therapeutic efficacy to propel market                 137

9.2.6        CANDIDATE SELECTION & VALIDATION              138

9.2.6.1    Critical requirement for regulatory approvals to drive market                 138

9.3           DISEASE DIAGNOSIS & PROGNOSIS         139

9.3.1        INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET   139

9.4           CLINICAL WORKFLOW  140

9.4.1        STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET             140

9.5           TRAINING & EDUCATION            141

9.5.1        UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH                 141

10            AI IN PATHOLOGY MARKET, BY END USER          143

10.1         INTRODUCTION              144

10.2         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES       144

10.2.1      GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET             144

10.3         HOSPITALS & REFERENCE LABORATORIES          145

10.3.1      INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH        145

10.4         ACADEMIC & RESEARCH INSTITUTES    147

10.4.1      GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND 147

11            AI IN PATHOLOGY MARKET, BY REGION               148

11.1         INTRODUCTION              149

11.2         NORTH AMERICA             149

11.2.1      MACROECONOMIC OUTLOOK  149

11.2.2      US           153

11.2.2.1  High healthcare expenditure and improvements in cloud computing platforms to propel market              153

11.2.3      CANADA               157

11.2.3.1  Increasing adoption of deep learning for advanced healthcare diagnostics to drive market 157

11.3         EUROPE               160

11.3.1      MACROECONOMIC OUTLOOK  160

11.3.2      UK          163

11.3.2.1  Increased focus on drug discovery and development to boost demand  163

11.3.3      GERMANY           166

11.3.3.1  Availability of funding for AI initiatives to fuel uptake  166

11.3.4      FRANCE                169

11.3.4.1  Increasing adoption of big data in healthcare computing to fuel uptake    169

11.3.5      ITALY    172

11.3.5.1  Digital transformation and innovation in healthcare to support market growth       172

11.3.6      SPAIN    175

11.3.6.1  Increased workforce shortage to fuel market   175

11.3.7      REST OF EUROPE             178

11.4         ASIA PACIFIC     181

11.4.1      MACROECONOMIC OUTLOOK  181

11.4.2      CHINA  185

11.4.2.1  Rising cases of infectious and chronic diseases to fuel demand                 185

11.4.3      JAPAN   188

11.4.3.1  Advanced healthcare infrastructure to propel market    188

11.4.4      INDIA    191

11.4.4.1  Growing focus on healthcare digitization to boost demand                 191

11.4.5      REST OF ASIA PACIFIC   195

11.5         LATIN AMERICA                198

11.5.1      MACROECONOMIC OUTLOOK  198

11.5.2      BRAZIL 201

11.5.2.1  Strategic investments for AI adoption to support market growth                 201

11.5.3      MEXICO                204

11.5.3.1  Growth in pharmaceutical R&D to drive market             204

11.5.4      REST OF LATIN AMERICA             207

11.6         MIDDLE EAST & AFRICA                210

11.6.1      MACROECONOMIC OUTLOOK  210

11.6.2      GCC COUNTRIES              213

11.6.2.1  Increasing investments for expansion of technological expertise to support growth 213

11.6.3      REST OF MIDDLE EAST & AFRICA             216

12            COMPETITIVE LANDSCAPE         220

12.1         INTRODUCTION              220

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            220

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET             221

12.3         REVENUE ANALYSIS, 2020−2024                 223

12.4         MARKET SHARE ANALYSIS, 2024                 223

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 226

12.5.1      STARS   226

12.5.2      EMERGING LEADERS     226

12.5.3      PERVASIVE PLAYERS      226

12.5.4      PARTICIPANTS 226

12.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         228

12.5.5.1  Company footprint               228

12.5.5.2  Offering footprint 229

12.5.5.3  Use case footprint 230

12.5.5.4  End user footprint                 231

12.5.5.5  Region footprint   232

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        233

12.6.1      PROGRESSIVE COMPANIES         233

12.6.2      RESPONSIVE COMPANIES            233

12.6.3      DYNAMIC COMPANIES  233

12.6.4      STARTING BLOCKS         233

12.6.5      COMPETITIVE BENCHMARKING               235

12.7         COMPANY VALUATION & FINANCIAL METRICS 236

12.7.1      FINANCIAL METRICS      236

12.7.2      COMPANY VALUATION 236

12.8         BRAND/PRODUCT COMPARISON             237

12.9         COMPETITIVE SCENARIO             237

12.9.1      PRODUCT/SERVICE LAUNCHES & APPROVALS  237

12.9.2      DEALS  239

12.9.3      OTHER DEVELOPMENTS              241

13            COMPANY PROFILES      242

13.1         KEY PLAYERS     242

13.1.1      KONINKLIJKE PHILIPS N.V.          242

13.1.1.1  Business overview 242

13.1.1.2  Products/Services offered   243

13.1.1.3  Recent developments           244

13.1.1.3.1                Deals      244

13.1.1.4  MnM view              244

13.1.1.4.1                Key strengths        244

13.1.1.4.2                Strategic choices   244

13.1.1.4.3                Weaknesses & competitive threats     244

13.1.2      F. HOFFMANN-LA ROCHE LTD. 245

13.1.2.1  Business overview 245

13.1.2.2  Products/Services offered   246

13.1.2.3  Recent developments           247

13.1.2.3.1                Product/Service launches & approvals              247

13.1.2.3.2                Deals      248

13.1.2.4  MnM view              248

13.1.2.4.1                Key strengths        248

13.1.2.4.2                Strategic choices   248

13.1.2.4.3                Weaknesses & competitive threats     248

13.1.3      HOLOGIC, INC. 249

13.1.3.1  Business overview 249

13.1.3.2  Products/Services offered   250

13.1.3.3  Recent developments           251

13.1.3.3.1                Product/Service launches & approvals              251

13.1.3.4  MnM view              251

13.1.3.4.1                Key strengths        251

13.1.3.4.2                Strategic choices   251

13.1.3.4.3                Weaknesses & competitive threats     251

13.1.4      AKOYA BIOSCIENCES, INC.          252

13.1.4.1  Business overview 252

13.1.4.2  Products/Services offered   253

13.1.4.3  Recent developments           254

13.1.4.3.1                Deals      254

13.1.4.4  MnM view              255

13.1.4.4.1                Key strengths        255

13.1.4.4.2                Strategic choices   255

13.1.4.4.3                Weaknesses & competitive threats     255

13.1.5      AIFORIA TECHNOLOGIES PLC   256

13.1.5.1  Business overview 256

13.1.5.2  Products/Services offered   257

13.1.5.3  Recent developments           258

13.1.5.3.1                Deals      258

13.1.5.4  MnM view              260

13.1.5.4.1                Key strengths        260

13.1.5.4.2                Strategic choices   260

13.1.5.4.3                Weaknesses & competitive threats     260

13.1.6      INDICA LABS INC.            261

13.1.6.1  Business overview 261

13.1.6.2  Products/Services offered   261

13.1.6.3  Recent developments           262

13.1.6.3.1                Product/Service launches & approvals              262

13.1.6.3.2                Deals      263

13.1.6.3.3                Expansions             265

13.1.7      OPTRASCAN       266

13.1.7.1  Business overview 266

13.1.7.2  Products/Services offered   266

13.1.7.3  Recent developments           267

13.1.7.3.1                Other developments             267

13.1.8      IBEX MEDICAL ANALYTICS LTD.               268

13.1.8.1  Business overview 268

13.1.8.2  Products/Services offered   268

13.1.8.3  Recent developments           269

13.1.8.3.1                Product/Service launches & approvals              269

13.1.8.3.2                Deals      270

13.1.9      MINDPEAK GMBH            272

13.1.9.1  Business overview 272

13.1.9.2  Products/Services offered   272

13.1.9.3  Recent developments           273

13.1.9.3.1                Product/Service launches & approvals              273

13.1.9.3.2                Deals      273

13.1.9.3.3                Other developments             274

13.1.10   TRIBUN HEALTH              275

13.1.10.1                 Business overview 275

13.1.10.2                 Products/Services offered   275

13.1.10.3                 Recent developments           276

13.1.10.3.1             Deals      276

13.1.11   TECHCYTE, INC.               277

13.1.11.1                 Business overview 277

13.1.11.2                 Products/Services offered   277

13.1.11.3                 Recent developments           278

13.1.11.3.1             Product/Service launches & approvals              278

13.1.11.3.2             Deals      278

13.1.11.3.3             Other developments             279

13.1.12   DEEP BIO INC.   280

13.1.12.1                 Business overview 280

13.1.12.2                 Products/Services offered   280

13.1.12.3                 Recent developments           281

13.1.12.3.1             Deals      281

13.1.13   LUMEA INC.        282

13.1.13.1                 Business overview 282

13.1.13.2                 Products/Services offered   282

13.1.13.3                 Recent developments           283

13.1.13.3.1             Deals      283

13.1.14   VISIOPHARM     284

13.1.14.1                 Business overview 284

13.1.14.2                 Products/Services offered   284

13.1.14.3                 Recent developments           285

13.1.14.3.1             Product/Service launches & approvals              285

13.1.14.3.2             Expansions             285

13.1.15   AETHERAI           287

13.1.15.1                 Business overview 287

13.1.15.2                 Products/Services offered   287

13.1.15.3                 Recent developments           288

13.1.15.3.1             Deals      288

13.1.16   AIOSYN 289

13.1.16.1                 Business overview 289

13.1.16.2                 Products/Services offered   289

13.1.16.3                 Recent developments           290

13.1.16.3.1             Product/Service launches & approvals              290

13.1.16.3.2             Deals      291

13.1.16.3.3             Other developments             291

13.1.17   PAIGE AI, INC.   292

13.1.17.1                 Business overview 292

13.1.17.2                 Products/Services offered   292

13.1.17.3                 Recent developments           293

13.1.17.3.1             Product/Service launches & approvals              293

13.1.17.3.2             Deals      295

13.1.17.3.3             Other developments             295

13.1.18   PROSCIA, INC.   296

13.1.18.1                 Business overview 296

13.1.18.2                 Products/Services offered   296

13.1.18.3                 Recent developments           297

13.1.18.3.1             Product/Service launches & approvals              297

13.1.18.3.2             Deals      298

13.1.18.3.3             Other developments             298

13.1.19   PATHAI, INC.     299

13.1.19.1                 Business overview 299

13.1.19.2                 Products/Services offered   299

13.1.19.3                 Recent developments           300

13.1.19.3.1             Product/Service launches & approvals              300

13.1.19.3.2             Deals      301

13.1.20   TEMPUS LABS, INC.         303

13.1.20.1                 Business overview 303

13.1.20.2                 Products/Services offered   304

13.1.20.3                 Recent developments           304

13.1.20.3.1             Product/Service launches & approvals              304

13.2         OTHER PLAYERS              305

13.2.1      KONFOONG BIOINFORMATION TECH CO., LTD.                 305

13.2.2      DOMORE DIAGNOSTICS AS         306

13.2.3      QRITIVE               306

13.2.4      DEEPATHOLOGY LTD   307

13.2.5      4D PATH INC.    308

14            APPENDIX           309

14.1         DISCUSSION GUIDE        309

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                316

14.3         CUSTOMIZATION OPTIONS        318

14.4         RELATED REPORTS         318

14.5         AUTHOR DETAILS           319

LIST OF TABLES

TABLE 1                EXCHANGE RATES, 2021–2024      31

TABLE 2                ROLE OF PLAYERS IN MARKET ECOSYSTEM                 66

TABLE 3                REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           70

TABLE 4                US FDA: MEDICAL DEVICE CLASSIFICATION                 71

TABLE 5                US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              71

TABLE 6                CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      72

TABLE 7                EUROPE: CLASSIFICATION OF IVD DEVICES                 72

TABLE 8                JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA   74

TABLE 9                CHINA: CLASSIFICATION OF MEDICAL DEVICES                 74

TABLE 10              INDICATIVE PRICING ANALYSIS, BY OFFERING                 75

TABLE 11              IMPACT OF PORTER’S FORCES  77

TABLE 12              JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET  79

TABLE 13              KEY PATENTS IN AI IN PATHOLOGY MARKET                 81

TABLE 14              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)        82

TABLE 15              KEY BUYING CRITERIA, BY END USER    83

TABLE 16              UNMET NEEDS OF END USERS  84

TABLE 17              AI IN PATHOLOGY MARKET: END USER EXPECTATIONS                84

TABLE 18              LIST OF CONFERENCES AND EVENTS, 2025–2026                 85

TABLE 19              IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2023 (USD THOUSAND)      95

TABLE 20              EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2023 (USD MILLION)            96

TABLE 21              RECIPROCAL TARIFF RATES ADJUSTED BY US                 97

TABLE 22              TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS         97

TABLE 23              EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT                 98

TABLE 24              AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)            102

TABLE 25              AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 103

TABLE 26              AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 104

TABLE 27             AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            105

TABLE 28              AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023–2030 (USD MILLION)         106

TABLE 29              AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            106

TABLE 30             AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            108

TABLE 31              AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            109

TABLE 32              AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            111

TABLE 33              AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)    113

TABLE 34              AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            114

TABLE 35              AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            116

TABLE 36              AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            117

TABLE 37              AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            118

TABLE 38              AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)            120

TABLE 39              AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            121

TABLE 40              AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            122

TABLE 41              AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            123

TABLE 42              AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            124

TABLE 43              AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 125

TABLE 44              AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            126

TABLE 45              AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            127

TABLE 46              AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            128

TABLE 47              AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)       130

TABLE 48              DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY     131

TABLE 49              AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2023–2030 (USD MILLION)            131

TABLE 50              AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            132

TABLE 51              AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            133

TABLE 52              AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 134

TABLE 53              AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            135

TABLE 54              AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            136

TABLE 55              AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            137

TABLE 56              AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            138

TABLE 57              AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            140

TABLE 58              AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 141

TABLE 59              AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 142

TABLE 60              AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)       144

TABLE 61              AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  145

TABLE 62              AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            146

TABLE 63              AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            147

TABLE 64              AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)       149

TABLE 65              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 66              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)          151

TABLE 67              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            152

TABLE 68              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            152

TABLE 69              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)          153

TABLE 70              NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            153

TABLE 71              US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)            155

TABLE 72              US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)            155

TABLE 73              US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)          156

TABLE 74              US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)            156

TABLE 75              US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)            157

TABLE 76              CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     158

TABLE 77              CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   158

TABLE 78              CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            159

TABLE 79              CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                159

TABLE 80              CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                160

TABLE 81              EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            161

TABLE 82              EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     161

TABLE 83              EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   162

TABLE 84              EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            162

TABLE 85              EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                163

TABLE 86              EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                163

TABLE 87              UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)            164

TABLE 88              UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)            165

TABLE 89              UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            165

TABLE 90              UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)            166

TABLE 91              UK: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)            166

TABLE 92              GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     167

TABLE 93              GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   167

TABLE 94              GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            168

TABLE 95              GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                168

TABLE 96              GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                169

TABLE 97              FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     170

TABLE 98              FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   170

TABLE 99              FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            171

TABLE 100            FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                171

TABLE 101            FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                172

TABLE 102            ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     173

TABLE 103            ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   173

TABLE 104            ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            174

TABLE 105            ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                174

TABLE 106            ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                175

TABLE 107            SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     176

TABLE 108            SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   176

TABLE 109            SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            177

TABLE 110            SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                177

TABLE 111            SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                178

TABLE 112            REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            179

TABLE 113            REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            179

TABLE 114            REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            180

TABLE 115            REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            180

TABLE 116            REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            181

TABLE 117            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            183

TABLE 118            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            183

TABLE 119            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            184

TABLE 120            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            184

TABLE 121            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            185

TABLE 122            ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            185

TABLE 123            CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     186

TABLE 124            CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   186

TABLE 125            CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            187

TABLE 126            CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                187

TABLE 127            CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                188

TABLE 128            JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       189

TABLE 129            JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     189

TABLE 130            JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   190

TABLE 131            JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            190

TABLE 132            JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                191

TABLE 133            JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                191

TABLE 134            INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     192

TABLE 135            INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   193

TABLE 136            INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            193

TABLE 137            INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                194

TABLE 138            INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                194

TABLE 139            REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            195

TABLE 140            REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            196

TABLE 141            REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            196

TABLE 142            REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            197

TABLE 143            REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            197

TABLE 144            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            199

TABLE 145            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            199

TABLE 146            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            200

TABLE 147            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            200

TABLE 148            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            201

TABLE 149            LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            201

TABLE 150            BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     202

TABLE 151            BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   202

TABLE 152            BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            203

TABLE 153            BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                203

TABLE 154            BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                204

TABLE 155            MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     205

TABLE 156            MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)   205

TABLE 157            MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            206

TABLE 158            MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)                206

TABLE 159            MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                207

TABLE 160            REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            208

TABLE 161            REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            208

TABLE 162            REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)                 209

TABLE 163            REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            209

TABLE 164            REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            210

TABLE 165            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION,

2023–2030 (USD MILLION)            211

TABLE 166            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            211

TABLE 167            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            212

TABLE 168            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            212

TABLE 169            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            213

TABLE 170            MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            213

TABLE 171            GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            214

TABLE 172            GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION,

2023–2030 (USD MILLION)            215

TABLE 173            GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,

2023–2030 (USD MILLION)            215

TABLE 174            GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            216

TABLE 175            GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            216

TABLE 176            REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)                 217

TABLE 177            REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)            217

TABLE 178            REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)            218

TABLE 179            REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE,

2023–2030 (USD MILLION)            218

TABLE 180            REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)                 219

TABLE 181            OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES       221

TABLE 182            AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION 224

TABLE 183            OFFERING FOOTPRINT 229

TABLE 184            USE CASE FOOTPRINT  230

TABLE 185            END USER FOOTPRINT 231

TABLE 186            REGION FOOTPRINT     232

TABLE 187            AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES    235

TABLE 188            AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          235

TABLE 189            AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025           237

TABLE 190            AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–APRIL 2025                239

TABLE 191            AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– APRIL 2025      241

TABLE 192            KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW          242

TABLE 193            KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED               243

TABLE 194            KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–APRIL 2025                244

TABLE 195            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          245

TABLE 196            F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED               246

TABLE 197            F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−MARCH 2025           247

TABLE 198            F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−MARCH 2025       248

TABLE 199            HOLOGIC, INC.: COMPANY OVERVIEW  249

TABLE 200            HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED             250

TABLE 201            HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025           251

TABLE 202            AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW          252

TABLE 203            AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED 253

TABLE 204            AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021−APRIL 2025              254

TABLE 205            AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW          256

TABLE 206            AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED 257

TABLE 207            AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−APRIL 2025              258

TABLE 208            INDICA LABS INC.: COMPANY OVERVIEW                 261

TABLE 209            INDICA LABS INC.: PRODUCTS/SERVICES OFFERED             261

TABLE 210            INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021−APRIL 2025          262

TABLE 211            INDICA LABS INC.: DEALS, JANUARY 2021−APRIL 2025              263

TABLE 212            INDICA LABS INC.: EXPANSIONS, JANUARY 2021–APRIL 2025           265

TABLE 213            OPTRASCAN: COMPANY OVERVIEW       266

TABLE 214            OPTRASCAN: PRODUCTS/SERVICES OFFERED                 266

TABLE 215            OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025            267

TABLE 216            IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW          268

TABLE 217            IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED               268

TABLE 218            IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025           269

TABLE 219            IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–APRIL 2025            270

TABLE 220            MINDPEAK GMBH: COMPANY OVERVIEW                 272

TABLE 221            MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED             272

TABLE 222            MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            273

TABLE 223            MINDPEAK GMBH: DEALS, JANUARY 2021–APRIL 2025        273

TABLE 224            MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025            274

TABLE 225            TRIBUN HEALTH: COMPANY OVERVIEW                 275

TABLE 226            TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED             275

TABLE 227            TRIBUN HEALTH: DEALS, JANUARY 2021–APRIL 2025        276

TABLE 228            TECHCYTE, INC.: COMPANY OVERVIEW                 277

TABLE 229            TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED             277

TABLE 230            TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            278

TABLE 231            TECHCYTE, INC.: DEALS, JANUARY 2021–APRIL 2025        278

TABLE 232            TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025            279

TABLE 233            DEEP BIO INC.: COMPANY OVERVIEW   280

TABLE 234            DEEP BIO INC.: PRODUCTS/SERVICES OFFERED                 280

TABLE 235            DEEP BIO INC.: DEALS, JANUARY 2021–APRIL 2025        281

TABLE 236            LUMEA INC.: COMPANY OVERVIEW        282

TABLE 237            LUMEA INC.: PRODUCTS/SERVICES OFFERED                 282

TABLE 238            LUMEA INC.: DEALS, JANUARY 2021–APRIL 2025                 283

TABLE 239            VISIOPHARM: COMPANY OVERVIEW      284

TABLE 240            VISIOPHARM: PRODUCTS/SERVICES OFFERED                 284

TABLE 241            VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            285

TABLE 242            VISIOPHARM: EXPANSIONS, JANUARY 2021– APRIL 2025           285

TABLE 243            AETHERAI: COMPANY OVERVIEW            287

TABLE 244            AETHERAI: PRODUCTS/SERVICES OFFERED                 287

TABLE 245            AETHERAI: DEALS, JANUARY 2021– APRIL 2025                 288

TABLE 246            AIOSYN: COMPANY OVERVIEW 289

TABLE 247            AIOSYN: PRODUCTS/SERVICES OFFERED                 289

TABLE 248            AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            290

TABLE 249            AIOSYN: DEALS, JANUARY 2021–APRIL 2025                 291

TABLE 250            AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025                291

TABLE 251            PAIGE AI, INC.: COMPANY OVERVIEW    292

TABLE 252            PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED                 292

TABLE 253            PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021– APRIL 2025           293

TABLE 254            PAIGE AI, INC.: DEALS, JANUARY 2021–APRIL 2025        295

TABLE 255            PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025            295

TABLE 256            PROSCIA, INC.: COMPANY OVERVIEW    296

TABLE 257            PROSCIA, INC.: PRODUCTS/SERVICES OFFERED                 296

TABLE 258            PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            297

TABLE 259            PROSCIA, INC.: DEALS, JANUARY 2021–APRIL 2025        298

TABLE 260            PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025            298

TABLE 261            PATHAI, INC.: COMPANY OVERVIEW      299

TABLE 262            PATHAI, INC.: PRODUCTS/SERVICES OFFERED                 299

TABLE 263            PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            300

TABLE 264            PATHAI, INC.: DEALS, JANUARY 2021–APRIL 2025                 301

TABLE 265            TEMPUS LABS, INC.: COMPANY OVERVIEW                 303

TABLE 266            TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED             304

TABLE 267            TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–APRIL 2025            304

TABLE 268            KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW       305

TABLE 269            DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW          306

TABLE 270            QRITIVE: COMPANY OVERVIEW                306

TABLE 271            DEEPPATH: COMPANY OVERVIEW          307

TABLE 272            4D PATH INC.: COMPANY OVERVIEW     308

LIST OF FIGURES

FIGURE 1              RESEARCH DESIGN         33

FIGURE 2              KEY PRIMARY SOURCES                36

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION                37

FIGURE 4              MARKET SIZE ESTIMATION PROCESS     38

FIGURE 5              KEY INSIGHTS FROM INDUSTRY EXPERTS                 39

FIGURE 6              BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY   40

FIGURE 7              AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030)              41

FIGURE 8              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 42

FIGURE 9              TOP-DOWN APPROACH                43

FIGURE 10            DATA TRIANGULATION METHODOLOGY                 44

FIGURE 11            AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)                47

FIGURE 12            AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION)               48

FIGURE 13            AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)                48

FIGURE 14            AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)                49

FIGURE 15            AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT          50

FIGURE 16            DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET               51

FIGURE 17            NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD         52

FIGURE 18            PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024       53

FIGURE 19            INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       54

FIGURE 20            AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     55

FIGURE 21            HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF

HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)        62

FIGURE 22            TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS   63

FIGURE 23            ECOSYSTEM ANALYSIS  65

FIGURE 24            VALUE CHAIN ANALYSIS               67

FIGURE 25            EUROPE: IVDR TIMELINE             73

FIGURE 26            PORTER’S FIVE FORCES 76

FIGURE 27            NUMBER OF PATENTS PUBLISHED, JANUARY 2017−APRIL 2025              78

FIGURE 28            NUMBER OF PATENT DOCUMENTS, BY JURISDICTION  79

FIGURE 29            TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS),

JANUARY 2017–APRIL 2025            80

FIGURE 30            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER                82

FIGURE 31            KEY BUYING CRITERIA, BY END USER    83

FIGURE 32            FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET               87

FIGURE 33            MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY     89

FIGURE 34            IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2023 (USD)                94

FIGURE 35            EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2023 (USD THOUSAND)      95

FIGURE 36            NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT          150

FIGURE 37            ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT          182

FIGURE 38            REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION)          223

FIGURE 39            AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024)                224

FIGURE 40            AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         227

FIGURE 41            AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT       228

FIGURE 42            AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024                234

FIGURE 43            EV/EBITDA OF KEY VENDORS   236

FIGURE 44            YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

AI IN PATHOLOGY VENDORS     236

FIGURE 45            BRAND/PRODUCT COMPARISON             237

FIGURE 46            KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)             243

FIGURE 47            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)             246

FIGURE 48            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 250

FIGURE 49            AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)             253

FIGURE 50            AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)             256

FIGURE 51            TEMPUS: COMPANY SNAPSHOT (2024)  303